Characteristics and evolution of patients treated with Biologicals in severe asthma of Getafe University hospital

Characteristics and Evolution of Patients treated with Biologicals in Severe Asthma of Getafe University Hospital. <bold>Introduction:</bold> At the final stage of asthma treatment, biologicals are employed to achieve asthma control while also reducing the consumption of systemic corticosteroids. Once treatment is initiated, is essential to review the response. The objective is to assess the response to biological treatment in patients with severe asthma. <bold>Methods:</bold> A retrospective descriptive study treated for at least one year with different biologicals. Patients were divided according to the biological they received for at least 12 consecutive months. Demographic, clinical, functional, biomarkers, FEOS and Exacto Scores were analyzed. <bold>Results:</bold> 50 patients were analyzed, of whom 70.8% were women with an average age of 55.8±14.2 years and an average BMI of 29.84±6.4 kg/m2.94% of this group had a cumulative dose of more than 1 gram of prednisone. Clinical characteristics and comorbidities are detailed in Figure 1A. Mepolizumab group showed an increase of 141 ml in FEV1 and ACT of 4 points. 50% of patients reduced the dose of systematic corticosteroids. FEOS score of 77 and an EXACTO score of 7. Benralizumab group showed an increase of 40ml in FEV1 and ACT of 6 points. 100% of the patients reduced de dose of systematic corticosteroids. FEOS score of 56 and EXACTO score of 4. The 80% of the dupilumab group reduced the dose of systematic corticosteroids. FEOS score of 77 and an EXACTO score of 6. Functional characteristics and control features are detailed in Table 2. <bold>Conclusions:</bold> It is important to assess the response to achieve clinical remission and not just focus on reducing exacerbations.